Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing ...

Pfizer (PFE) remains in focus for income oriented investors, with recent returns ranging from a 2.1% decline over the past ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Right now, Pfizer's dividend payout ratio is above 100%. That suggests the dividend comes with some risk, which is true.

Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in ...

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...

Pfizer stands as one of the largest drug makers in the world. It faces normal industry challenges, but it also has a lofty payout ratio. Its latest acquisition shows what it is capable of doing to get ...

--Currently down nine consecutive days; down 11.06% over this period --Longest losing streak since Feb. 25, 2020, when it fell for nine straight trading days --Worst nine-day stretch since the nine ...

Notes landmark agreement with U.S. government: Says voluntary agreement provides greater clarity; reduces uncertainty around tariffs and pricing; allows investment in future innovation and growth.